Biogen (NASDAQ:BIIB) operates in the biotechnology sector, focusing on developing therapies for neurological and neurodegenerative diseases. This company is renowned for its work in multiple sclerosis (MS) treatments and has expanded its research and product portfolio to include treatments for Alzheimer's disease, spinal muscular atrophy (SMA), and other serious neurological disorders. With a strong commitment to innovative science, its objectives include advancing the boundaries of neuroscience, improving the lives of those affected by serious diseases, and pursuing a sustainable research and development pipeline. Biogen's projects span from early discovery stages to late-stage clinical trials, aiming to address some of the most challenging unmet medical needs.